Design, Synthesis, and Antitumor Evaluation of Benzamide Derivatives Targeting HOXA1 Function

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Homeobox A1 (HOXA1) is an oncogenic transcription factor overexpressed in various solid tumors.
• High HOXA1 expression correlates with poor patient prognosis.
• Currently, no effective small-molecule agents target HOXA1 function.

Purpose of the Study:

• To identify and optimize small-molecule inhibitors targeting the HOXA1 transcription factor.
• To investigate the mechanism of action of the lead compound F2-15.
• To evaluate the in vivo antitumor efficacy of F2-15 in relevant cancer models.

Main Methods:

• Structure-based virtual screening to identify lead compound F2.
• Structure-activity relationship (SAR) optimization to develop F2-15.
• Mechanistic studies including protein level analysis, gene expression profiling, and DNA damage assays.
• In vivo evaluation in patient-derived xenograft (PDX) models of colorectal and triple-negative breast cancer.

Main Results:

• Compound F2 was identified as a HOXA1 binder, with F2-15 showing enhanced potency.
• F2-15 downregulates HOXA1 protein, suppresses its transcriptional activity, and induces DNA damage and apoptosis.
• F2-15 demonstrated significant antitumor efficacy in colorectal and triple-negative breast cancer PDX models.
• F2-15 exhibited synergistic effects when combined with cisplatin.

Conclusions:

• F2-15 is a potent small-molecule inhibitor of HOXA1.
• F2-15 exhibits promising preclinical antitumor activity in HOXA1-driven malignancies.
• F2-15 warrants further clinical development as a targeted therapy for HOXA1-driven cancers.